The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
 
Gopa Iyer
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Hiromichi Ebi
Honoraria - Amgen; Amoy Diagnostics; Chugai Pharma; Guardant Health AMEA; Incyte Japan; Konica Minolta; Merck Serono; Ono Pharmaceutical
Consulting or Advisory Role - Amgen; Amoy Diagnostics
Research Funding - Astellas Pharma; Loxo/Lilly (Inst)
 
Natalie Cook
Employment - CellCentric (I)
Stock and Other Ownership Interests - CellCentric (I)
Honoraria - Roche
Speakers' Bureau - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Loxo/Lilly (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); UCB (Inst)
Patents, Royalties, Other Intellectual Property - CUPiD Methylation assay. Patent application has now been filed at the UKIPO. The patent application number is GB2317261.2 (Inst)
Travel, Accommodations, Expenses - Roche
(OPTIONAL) Uncompensated Relationships - Roche
 
Xin Gao
Consulting or Advisory Role - ADC Therapeutics; Arvinas; Bayer; Flare Therapeutics; Hinova Pharmaceuticals; Loxo/Lilly
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio (Inst); Takeda (Inst)
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Melissa Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Consulting or Advisory Role - Astellas Pharma; Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Arlene Siefker-Radtke
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bicycle Therapeutics; G1 Therapeutics; Gilead Sciences; Immunomedics; Janssen; Loxo Oncology at Eli Lilly and Company; Merck; Pfizer; Seattle Genetics/Astellas; Taiho Pharmaceutical
Research Funding - Basilea Pharmaceutical (Inst); Bristol Myers Squibb Foundation (Inst); Janssen (Inst); Loxo Oncology at Eli Lilly and Company (Inst); Merck (Inst); Millennium (Inst); Nektar (Inst)
 
Miso Kim
Honoraria - Astellas Pharma; Bristol Myers Squibb; Janssen; Merck; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Boryung; Bristol-Myers Squibb; Janssen; Merck; MSD; Ono Pharmaceutical; Pfizer; Takeda; Yuhan
Travel, Accommodations, Expenses - Regeneron
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Debbie Robbrecht
Honoraria - Springer
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Axiom Healthcare Strategies; BMS; Gilead Sciences (Inst); J&J (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst)
Research Funding - Merck KGaA (Inst)
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Bernhard Eigl
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; EMD Serono/Merck; Gilead Sciences; Janssen; Merck; Pfizer; Roche Canada; Seagen
Consulting or Advisory Role - EMD Serono; Gilead Sciences
Travel, Accommodations, Expenses - EMD Serono
 
Clare Schaverien
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Brent Butts
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Eunice Yuen
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Sylwia Szymczak
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Xiang Zhao
Employment - Lilly
 
Ryan Widau
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb; Daichi-Sanchyo; DYANIA HEALTH; EMD Serono; EMD Serono; Exelixis; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen